Hi Dr Rassman,
I am not sure if you had seen the press release about neosil being acquired by another pharmaceutical company. Press release – PDF file
It all so goes onto say that peplin does not plan commence further development of neosil’s products until next year. So should we just cross neosh of the map now?
Just some background for casual readers that haven’t heard of this NEOSH101 product (it is a tetrapeptide aldehyde proteasome inhibitor) — A New Drug for Hair Loss, NEOSH101 by Neosil
I do not have any special knowledge of what Peplin will do with this. They don’t say the product is outright dead, but perhaps temporarily on ice? Here’s the interesting part of the press release, where it hints that they won’t be doing anything with it until at least sometime next year, though they will be advancing other Neosil products:
“Peplin intends to use the net cash obtained from the acquisition to continue the development of its lead product candidates PEP005 (ingenol mebutate) Gel for actinic keratosis and PEP005 (ingenol mebutate) Gel for basal cell carcinoma. Peplin believes that Neosil’s proprietary technologies in hair loss and acne could enable it to expand its product pipeline in the future, although Peplin does not expect to commence further development of these programs before 2009.”